Insomnia
📧 Sign up to get email alerts when something new happens for Insomnia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2007-10-02Clinical Trial Update: Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression [Phase 3]
Phase 3 study evaluating indiplon or placebo with sertraline in insomnia co-occurring with depression was terminated.
-
CLINICAL_TRIALS research · 2007-09-27Clinical Trial Update: Study on Magnetic Field Therapy to Improve Quality of Sleep and Reduction of Chronic Spine Pain [Phase 4]
Phase 4 clinical trial evaluating magnetic field therapy to improve sleep quality and reduce chronic back and neck pain; the study status is…
-
FDA approval · 2007-09-16FDA Approved: ESTAZOLAM — Supplemental Application (Novitium Pharma LLC)
The FDA approved a supplemental application for Estazolam filed by Novitium Pharma LLC.
-
CLINICAL_TRIALS trial_result · 2007-09-10Clinical Trial Update: Safety and Efficacy Study of APD125 in Patient With Insomnia [Phase 2]
This update notes the completion of a Phase 2 safety and efficacy study of APD125 in patients with insomnia.
-
FDA approval · 2007-08-17FDA Approved: ZOLPIDEM TARTRATE — Original Application (Torrent Pharmaceuticals Limited)
FDA approves Torrent Pharmaceuticals Limited's original application for zolpidem tartrate (generic) for the treatment of insomnia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2007-07-11FDA Approved: DOXEPIN HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental ANDA for doxepin hydrochloride from Mylan Pharmaceuticals Inc., enabling a generic version of the drug to en…
-
CLINICAL_TRIALS trial_result · 2007-06-29Clinical Trial Update: Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children [Phase 1, Phase 2]
This study provides single-dose pharmacokinetic and pharmacodynamic data for three zolpidem doses in children, across Phase 1/Phase 2 trials…
-
FDA approval · 2007-06-26FDA Approved: DOXEPIN HYDROCHLORIDE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for doxepin hydrochloride from Lannett Company, Inc., authorizing changes to an already approved pro…
-
CLINICAL_TRIALS trial_result · 2007-06-11Clinical Trial Update: Evaluation of a Food Supplement on Sleep Quality [NA]
A completed clinical trial evaluated an unspecified food supplement for improving sleep quality in individuals with insomnia.
-
FDA approval · 2007-05-04FDA Approved: ZOLPIDEM TARTRATE — Original Application (NorthStar Rx LLC)
FDA approves NorthStar Rx LLC's Zolpidem tartrate as an Original Application (ANDA) for a generic product to treat insomnia.
-
CLINICAL_TRIALS trial_result · 2007-04-27Clinical Trial Update: Sleep Disorders and Gastroesophageal Reflux Disease (GERD) [Phase 4]
Phase 4 clinical trial update from University of North Carolina investigating insomnia and gastroesophageal reflux disease; the study status…
-
CLINICAL_TRIALS trial_result · 2007-04-25Clinical Trial Update: Effects of Ramelteon on Driving Ability [Phase 1]
Phase 1 trial evaluating the impact of ramelteon on driving performance in individuals with insomnia. The update reports study findings.
-
FDA approval · 2007-04-23FDA Approved: ZOLPIDEM — Original Application (ACI Healthcare USA, Inc)
FDA approves the original application for zolpidem tartrate (generic zolpidem) filed by ACI Healthcare USA, Inc., for treatment of insomnia.
-
FDA approval · 2007-04-23FDA Approved: ZOLPIDEM TARTRATE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's original ANDA for zolpidem tartrate, a generic sleep medication for short-term treatment of insomnia.
-
FDA approval · 2007-04-23FDA Approved: ZOLPIDEM TARTRATE — Original Application (Sandoz Inc)
FDA approves Sandoz Inc.'s original abbreviated new drug application for zolpidem tartrate, enabling the marketing of a generic zolpidem tar…
-
CLINICAL_TRIALS trial_result · 2007-03-30Clinical Trial Update: A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia [Phase 3]
Phase 3 prospective active-reference study of gaboxadol in primary insomnia has completed.
-
CLINICAL_TRIALS trial_result · 2007-03-30Clinical Trial Update: A Study of Gaboxadol in Primary Insomnia [Phase 3]
Phase 3 clinical trial evaluating gaboxadol for primary insomnia has completed.
-
CLINICAL_TRIALS trial_result · 2007-03-30Clinical Trial Update: A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia [Phase 3]
This document reports the completion of a prospective open-label extension study of gaboxadol in primary insomnia (Phase 3).
-
CLINICAL_TRIALS trial_result · 2007-03-30Clinical Trial Update: A Study of Gaboxadol in Primary Insomnia [Phase 3]
A Phase 3 clinical trial evaluating gaboxadol for primary insomnia has completed.
-
CLINICAL_TRIALS trial_result · 2007-03-30Clinical Trial Update: A Study of Gaboxadol in Primary Insomnia [Phase 3]
Phase 3 study of gaboxadol for primary insomnia has completed.
-
FDA approval · 2007-03-28FDA Approved: AMBIEN — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approved a supplemental application for AMBIEN (zolpidem tartrate) filed by Cosette Pharmaceuticals, Inc., approving an update to the pr…
-
CLINICAL_TRIALS trial_result · 2007-01-29Clinical Trial Update: Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia [NA]
This clinical trial update reports on the safety and efficacy of an ambulatory biofeedback device for primary insomnia, with current status …
-
CLINICAL_TRIALS trial_result · 2007-01-26Clinical Trial Update: Efficacy Study of LY2422347 to Treat Insomnia [Phase 2]
A Phase 2 efficacy study of LY2422347 for insomnia has completed.
-
CLINICAL_TRIALS research · 2007-01-26Clinical Trial Update: Restless Legs Syndrome Exercise Intervention [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 exercise intervention being studied for restless legs syndrome, with insomnia as a co…
-
FDA approval · 2006-11-29FDA Approved: LORAZEPAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Lorazepam by Hikma Pharmaceuticals USA Inc., authorizing modifications under the supplement.